In the dynamic world of trading, identifying potential bounce plays is a strategic approach that savvy investors use to seize opportunities. Stocks that have recently experienced price declines, offering the possibility of a rebound in the near term, can often be bounce-play opportunities.
Let’s take a look at four bounce-play contenders.
HippoFi, Inc. (OTC:ORHB) has been making waves as a pioneering force in regenerative therapy, in the rapidly evolving world of biotechnology. With recent developments and strategic partnerships, ORHB could be poised for significant growth, presenting a unique opportunity for savvy investors.
Regenerative therapy is a game-changer in healthcare, addressing the challenges of limited donor supply and immune complications associated with organ and tissue transplants. By 2030, this industry is projected to be worth over $200 billion, and HippoFi is positioned to be a player in this transformative market.
HippoFi operates through three segments: Regenerative Therapeutics, Digital Payments, and AI. Its flagship subsidiary, PUR Biologics, leads the charge in regenerative therapeutics, offering a portfolio of innovative biological products and proprietary technologies. These products are designed for surgical spine procedures and advanced autologous cell therapies, addressing critical needs in bone growth and cartilage regeneration.
Recent corporate milestones have set HippoFi on a path of substantial growth. The US Patent Office granted PUR Biologics a patent for advanced cartilage regeneration and arthritis solutions. With over 350 million people worldwide and a quarter of American adults suffering from arthritis, this breakthrough holds immense potential.
Additionally, a partnership with Zimmer Biomet and a licensing deal with BPB Medica signify promising opportunities for HippoFi. The US launch of PURmarrow360, a surgical device for capturing a patient’s own bone marrow aspirate and stem cells, is expected to revolutionize bone growth procedures.
While HippoFi did not generate significant revenue in FY22 through the first half of FY23, its focus on R&D and strategic partnerships has set the stage for future growth. Analysts project revenues of $2.9 million for FY23, with substantial increases expected in FY24 and FY25.
Goldman Research has set a price target of $0.38 for ORHB, implying a potential upside of over 10x from current prices. Considering the multiple addressable markets, such as spinal biologics and immunotherapy, and the wide applicability of PURmarrow360, investors have good reason to keep a close eye on this stock.
ORHB may have experienced a minor dip in its stock price on Friday, but smart investors recognize that this presents an opportunity to acquire shares at a discounted price. With a robust portfolio of regenerative therapies, strategic partnerships, and a vision to profitability, HippoFi, Inc. is a penny stock to keep an eye on.
As the company continues to unlock value through innovation and expanding sales channels, ORHB could be a hidden gem in the world of biotech.
Marathon Gold Corp. (OTC:MGDPF) is currently trading at $0.49 USD, with a 3.62% decrease on September 22, 2023. This company is making significant strides in the gold mining sector, primarily driven by its Valentine Gold Project in Newfoundland and Labrador. The latest report from December 2022 outlined an encouraging feasibility study, indicating the potential for an annual gold production of 195,000 ounces over 12 years. It’s worth noting that the project received essential environmental clearances in 2022, and construction started in October of the same year, signaling a path toward full-scale operation.
The project boasts estimated proven mineral reserves of 1.43 moz and probable mineral reserves of 1.27 moz, with additional measured mineral resources of 2.06 moz and indicated mineral resources of 1.90 moz. These figures demonstrate the substantial gold reserves underpinning Marathon Gold Corp.’s growth potential.
Furthermore, the company’s commitment to sustainability, as highlighted in its 2022 Sustainability Report, aligns with the responsible mining practices that investors often seek. With the Valentine Gold Project being a significant employer in Newfoundland and Labrador and a strong focus on health and safety, Marathon Gold Corp.’s operations reflect a dedication to not only profitability but also the well-being of its workforce.
On September 22, T2 Biosystems Inc. (NASDAQ:TTOO) saw its stock trade at $0.25 USD, marking a decrease of 14.42% for the day. For savvy investors, this dip could present an opportunity to acquire shares at a reduced price.
T2 Biosystems is renowned for its expertise in rapidly detecting sepsis-causing pathogens and antibiotic resistance genes. The company’s recent achievement on September 19, 2023, was receiving FDA 510(k) clearance for the T2Biothreat Panel. This groundbreaking direct-from-blood molecular diagnostic test is designed to detect six biothreat pathogens, including anthrax, tularemia, glanders, melioidosis, plague, and typhus. These pathogens are considered significant threats by the U.S. Centers for Disease Control and Prevention.
The T2Biothreat Panel’s unique feature is its ability to provide accurate results within hours. In situations where timely treatment is critical, this technology can be a game-changer. Infections caused by these biothreat pathogens can result in mortality rates ranging from 40% to 90%, underscoring the importance of rapid detection.
T2 Biosystems’ FDA clearance is a testament to its commitment to biosecurity and its collaboration with the U.S. government and the Biomedical Advanced Research and Development Authority (BARDA).
For investors eyeing potential bounce opportunities, T2 Biosystems’ recent stock dip combined with its innovative biothreat detection technology may present a strategic entry point. It’s essential to conduct thorough research and consider the company’s growth potential when evaluating this opportunity.
ZyVersa Therapeutics Inc. (NASDAQ:ZVSA) has recently caught the attention of savvy investors as its stock dipped slightly, offering a potential entry point. The company operates in the clinical stage of the specialty biopharmaceutical sector, with a mission to address unmet medical needs in patients with renal and inflammatory diseases.
ZyVersa’s therapeutic development pipeline is being actively advanced by innovative proprietary technologies. One of these, the Cholesterol Efflux Mediator VAR 200, is geared towards treating kidney diseases, while the Inflammasome ASC Inhibitor IC 100 is focused on mitigating damaging inflammation linked to various CNS and inflammatory diseases.
A notable recent development reinforces the company’s potential. On September 22, 2023, ZyVersa announced research published in The Journal of Clinical Investigation. This research underscores how inflammation in the kidneys can trigger inflammation in the heart, particularly relevant for patients with chronic kidney disease (CKD).
The study reveals that CKD induces inflammatory responses characterized by increased levels of IL-1, IL-6, and CRP. This leads to the activation of NLRP3 inflammasomes in the heart’s atria, culminating in inflammation that contributes to the onset and progression of atrial fibrillation (AF).
In response to these findings, ZyVersa is actively developing the inflammatory ASC inhibitor IC 100. This innovative therapy is designed to inhibit inflammasomes and the associated extracellular ASC specks, reducing the propagation of IL-1 that triggers harmful inflammation and limiting its spread to surrounding tissues.
Investors are eyeing ZyVersa as it continues to demonstrate its commitment to addressing critical medical needs. With its focus on cutting-edge treatments and a potential rebound in stock price, ZyVersa Therapeutics is a company to watch in the dynamic biopharmaceutical landscape.
Disclaimers:CapitalGainsReport (CGR) is not operated by a licensed broker, a dealer, or a registered investment adviser. This content is for informational purposes only and is not intended to be investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performance that are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled. CapitalGainsReport (CGR) is owned by RazorPitch Inc. and has been retained by HippoFi Inc. to assist in the production and distribution of content related to ORHB. ‘CGR’ is responsible for the production and distribution of this content. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. This content is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained in this article constitutes a solicitation, recommendation, endorsement, or offer by CapitalGainsReport/RazorPitch or any third party service provider to buy or sell any securities or other financial instruments. All content in this article is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. CGR/RazorPitch is not a fiduciary by virtue of any persons use of or access to this content.